Cara Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Cara Therapeutics şirketinin toplam hissedar öz sermayesi $707.0K ve toplam borcu $40.6M olup, bu da borç-öz sermaye oranını 5740.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $51.3M ve $50.6M dir.

Anahtar bilgiler

5,740.2%

Borç/özkaynak oranı

US$40.58m

Borç

Faiz karşılama oranı	n/a
Nakit	US$42.04m
Eşitlik	US$707.00k
Toplam yükümlülükler	US$50.62m
Toplam varlıklar	US$51.33m

Son finansal sağlık güncellemeleri

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Feb 16

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Oct 25

Recent updates

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues

Nov 01

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jul 18

We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

May 29

Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

May 25

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Feb 16

The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

Dec 19

News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Nov 04

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Oct 25

Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Jul 20

Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

Jun 04

News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Mar 11

Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

Feb 15

We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

Feb 06

We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Oct 18

Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients

Sep 28

Cara Therapeutics hires new finance chief

Sep 12

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Sep 01

Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients

Aug 19

Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Aug 08

Calls A Much Safer Way To Buy Cara Therapeutics

Jun 24

We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Jun 15

Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

May 12

Taking A (Speculative) Position In Cara Therapeutics

Mar 21

Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Mar 09

Cara Therapeutics: De-Risked And Extremely Attractive

Dec 25

Checking Back In On Cara Therapeutics

Nov 01

Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA

Aug 21

The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically

Aug 15

Cara Therapeutics: 200% Upside Possible With FDA Approval

Aug 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CARA 'nin kısa vadeli varlıkları ( $47.9M ) kısa vadeli yükümlülüklerini ( $10.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: CARA şirketinin kısa vadeli varlıkları ( $47.9M ) uzun vadeli yükümlülüklerini ( $40.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CARA şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: CARA şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 5740.2% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CARA şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: CARA un, serbest nakit akışı her yıl % 7.4 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Cara Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Cara Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Nasdaq Grants Cara Therapeutics Additional 180 Days to Regain Compliance with Minimum Closing Bid Price Requirement

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Cara Therapeutics, Inc. Receives A Non-Compliance Notice from the Nasdaq Stock Market

Cara Therapeutics, Inc. Receives A Non-Compliance Notice from the Nasdaq Stock Market

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Recent updates

Cara Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 70% to US$1.52

Nasdaq Grants Cara Therapeutics Additional 180 Days to Regain Compliance with Minimum Closing Bid Price Requirement

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Cara Therapeutics, Inc. Announces Outcome from Dose-Finding Part A of the Kourage-1 Study

We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cara Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Cara Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

Price target decreased by 12% to US$4.90

Full year 2023 earnings: EPS and revenues miss analyst expectations

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Cara Therapeutics, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Cara Therapeutics, Inc. Receives A Non-Compliance Notice from the Nasdaq Stock Market

Cara Therapeutics, Inc. Receives A Non-Compliance Notice from the Nasdaq Stock Market

Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program

Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis

The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

Consensus revenue estimates decrease by 39%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

New major risk - Share price stability

Consensus revenue estimates increase by 19%

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Cara Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target decreased by 7.6% to US$17.29

New minor risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cara Therapeutics, Inc. Appoints Helen M. Boudreau as Member of Board and Audit Committee

Cara Therapeutics, Inc. Appoints Helen M. Boudreau to Board of Directors

New minor risk - Share price stability

Cara Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announces England’s National Institute for Health and Care Excellence has Recommended Kapruvia

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 53%

News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Price target decreased by 18% to US$19.38

Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cara Therapeutics Announces Appointment of Lisa Von Moltke, M.D., to Its Board of Directors

Cara Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients

Key Executive recently sold US$111k worth of stock

Cara Therapeutics, Inc Appoints Ryan Maynard as Principal Financial Officer and Principal Accounting Officer

Cara Therapeutics hires new finance chief

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Kapruvia® Gets Approval in Switzerland with Additional Regulatory Decisions

Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Cara Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Cara Therapeutics, Inc. Announces Positive Topline Results from Komfort Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

Calls A Much Safer Way To Buy Cara Therapeutics

We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Cara Therapeutics, Inc. Announces Resignation of Thomas Reilly as Chief Financial Officer, Effective on or About June 15, 2022

Consensus revenue estimates increase by 19%